Efficacy of recombinant human interleukin-10 in prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis in subjects with increased risk

Pancreas

Volumn 38, Issue 3, 2009, Pages 267-274

  Sherman, Stuart ^a   Cheng, Chi Liang ^a   Costamagna, Guido ^b   Binmoeller, Kenneth F ^c   Puespoek, Andreas ^d   Aithal, Guruprasad P ^e   Kozarek, Richard A ^f   Chen, Yang K ^g   Van Steenbergen, Werner ^h   Tenner, Scott ⁱ   Freeman, Martin ^j   Monroe, Paul ^k   Geffner, Michael ^l   Deviere, Jacques ^m  

^a INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^b CATHOLIC UNIVERSITY   (Italy)

^c CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^f VIRGINIA MASON MEDICAL CENTER   (United States)

^g UNIVERSITY OF COLORADO   (United States)

^h UNIVERSITY HOSPITALS LEUVEN   (Belgium)

ⁱ MAIMONIDES MEDICAL CENTER   (United States)

^j HENNEPIN COUNTY MEDICAL CENTER   (United States)

^k Richmond GI Research Group   (United States)

^l MERCK RESEARCH LABORATORIES   (United States)

^m ERASME HOSPITAL   (Belgium)

more..

Author keywords

Interleukin 10; Post ERCP pancreatitis

Indexed keywords

PLACEBO; RECOMBINANT INTERLEUKIN 10; INTERLEUKIN 10; RECOMBINANT PROTEIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PANCREATITIS; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; ACUTE DISEASE; AGED; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; RISK FACTOR; STATISTICS; TREATMENT FAILURE;

ACUTE DISEASE; ADULT; AGED; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; FEMALE; HUMANS; INCIDENCE; INJECTIONS, INTRAVENOUS; INTERLEUKIN-10; MALE; MIDDLE AGED; PANCREATITIS; PLACEBOS; RECOMBINANT PROTEINS; RISK FACTORS; TREATMENT FAILURE;

EID: 65549121589     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31819777d5     Document Type: Article

References (28)

1. Freeman ML. Adverse outcomes of ERCP. Gastrointest Endosc. 2002;56(suppl):S273-S282.
2. Freeman ML, DiSario JA, Nelson DB, et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc. 2001;54:425-434.
3. Masci E, Mariani A, Curioni S, et al. Risk factors for pancreatitis following endoscopic retrograde cholangiopancreatography: a meta-analysis. Endoscopy. 2003;35:830-834.
4. Fazel A, Quadri A, Catalano MF, et al. Does a pancreatic duct stent prevent post-ERCP pancreatitis? A prospective randomized study. Gastrointest Endosc. 2003;57:291-294.
5. Andriulli A, Leandro G, Niro G, et al. Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis. Gastrointest Endosc. 2000;51:1-7.
6. Murray B, Carter R, Imrie C, et al. Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangio-pancreatography. Gastroenterology. 2003;124:1786-1791.
7. Khoshbaten M, Khorram H, Madad L, et al. Role of diclofenac in reducing post-endoscopic retrograde cholangiopancreatography pancreatitis. J Gastroenterol Hepatol. 2007;23:11-16.
8. Cheon YK, Cho KB, Watkins JW, et al. Efficacy of diclofenac in the prevention of post-ERCP pancreatitis in predominately high-risk patients: a randomized double-blind prospective trial. Gastrointest Endosc. 2007;66:1126-1132.
9. Rongione AJ, Kusske AM, Kwan K, et al. Inteleukin-10 reduces the severity of acute pancreatitis in rats. Gastroenterology. 1997;112: 960-967.
10. Van Laethem JL, Marchant A, Delvaux A, et al. Interleukin-10 prevents necrosis in murine experimental acute pancreatitis. Gastroenterology. 1995;108:1917-1922.
11. Deviere J, Le Moine O, Van Laethem JL, et al. Interleukin 10 reduces the incidence of pancreatitis after therapeutic endoscopic retrograde cholangiopancreatography. Gastroenterology. 2001;120:498-505.
12. Dumot JA, Conwell DL, Zuccaro G, et al. A randomized, double blind study of interleukin 10 for the prevention of ERCP-induced pancreatitis. Am J Gastroenterol. 2001;96:2098-2102.
13. McHenry L, Monroe P, Duckworth F, et al. A randomized, double-blind pilot study of the efficacy of interleukin-10 (IL-10) in the prevention of post-ERCP pancreatitis. Am J Gastroenterol. 2001;96(suppl):S61-S62.
14. Epstein MS, DeHaemer T, Praschak PM, et al. Double blind, placebo controlled pilot study of the safety and activity of Interleukin-10 (RHuIL-10) in the prevention of acute pancreatitis following endoscopic retrograde cholangiopancreatography (ERCP). Am J Gastroenterol. 2001;96(suppl):S85- S86.
15. Singh P, Lee T, Davidoff S, et al. Efficacy of interleukin-10 (IL-10) in the prevention of post-ERCP pancreatitis: a meta-analysis. Gastrointest Endosc. 2002;55:AB150.
16. Cotton PB, Lehman GA, Vennes J, et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc. 1991;37:383-393.
17. Saluja AK, Steer ML. Pathophysiology of pancreatitis. Role of cytokines and other mediators of inflammation. Digestion. 1999;60(suppl 1):27-33.
18. Leser HG, Gross V, Scheibenbogen C, et al. Elevation of serum interleukin-6 concentration precedes acute-phase response and reflects severity in acute pancreatitis. Gastroenterology. 1991;101:782-785.
19. Pezzilli R, Billi P, Miniero R, et al. Serum interleukin-6, interleukin-8, and β2-microglobulin in early assessment of severity of acute pancreatitis. Comparison with serum C-reactive protein. Dig Dis Sci. 1995;40:2341-2348.
20. Grewal HP, Kotb M, el Din AM, et al. Induction of tumor necrosis factor in severe acute pancreatitis and its subsequent reduction after hepatic passage. Surgery. 1994;115:213-221.
21. Norman J, Franz M, Messina J, et al. Interleukin-1 receptor antagonist decreases severity of experimental acute pancreatitis. Surgery. 1995;117:648-655.
22. Fiorentino DF, Zlotnik A, Mosmann TR, et al. IL-10 inhibits cytokine production by activated macrophages. J Immunol. 1991;147:3815-3822.
23. Gerard C, Bruyns C, Marchant A, et al. Interleukin-10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med. 1993;177:547-550.
24. Freeman ML. Prevention of post-ERCP pancreatitis: pharmacologic solution or patient selection and pancreatic stents [editorial]? Gastroenterology. 2003;124:1977-1980.
25. Andriulli A, Clemente R, Solmi L, et al. The Italian group for prevention of acute pancreatitis (GIPPA study). Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial. Gastrointest Endosc. 2002;56:488-495.
26. Testoni PA, Bagnolo F, Andriulli A, et al. Octreotide 24-h prophylaxis in patients at high risk for post-ERCP pancreatitis: results of a multicenter, randomized, controlled trial. Aliment Pharmacol Ther. 2001;15:965-972.
27. Rabenstein T, Fischer B, WieQner V, et al. Low-molecular-weight heparin does not prevent acute post-ERCP pancreatitis. Gastrointest Endosc. 2004;59:606-613.
28. Schreiber S, Fedorak RN, Nielsen OH, et al. The Crohn's disease IL-10 cooperative study group. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Gastroenterology. 2000;119:1461-1472.